Showing results (611-620 of 727) with videos related to
Sort By:
Pageof 73
British Journal of Cancer|July 1, 2015
Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancerP A Jänne, I Smith, G McWalter, et al.Multiple Sclerosis and Related Disorders|June 30, 2019
Response heterogeneity to home-based restorative cognitive rehabilitation in multiple sclerosis: An exploratory studyTom A Fuchs, Stefano Ziccardi, Michael G Dwyer, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 30, 2026
Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small cell lung cancer: 7-year update from the phase 3 CROWN studyA T Shaw, B J Solomon, E Felip, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2015
Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain MetastasesDaniel B Costa, Alice T Shaw, Sai-Hong I Ou, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 29, 2019
Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged NSCLCMakoto Nishio, Enriqueta Felip, Sergey Orlov, et al.The Lancet. Oncology|November 1, 2019
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trialAlice T Shaw, Benjamin J Solomon, Rita Chiari, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 24, 2019
Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX StudyD Ross Camidge, Rafal Dziadziuszko, Solange Peters, et al.Clinical Pharmacokinetics|December 11, 2023
Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, UGT, and P-Glycoprotein Substrates in Patients with Advanced Non-Small Cell Lung CancerJoseph Chen, Alessandra Bearz, Dong-Wan Kim, et al.The Lancet. Oncology|November 13, 2016
Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trialScott N Gettinger, Lyudmila A Bazhenova, Corey J Langer, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 14, 2019
Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001A T Shaw, G J Riely, Y-J Bang, et al.Pageof 73